BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 38852942)

  • 1. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019.
    Girardi M; Carlson K; Huang X; Corman SL; Edmundson P; Schmier J; Kale HP; Raina R; Foss F
    J Dermatolog Treat; 2024 Dec; 35(1):2360568. PubMed ID: 38852942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?
    Akilov OE
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal photopheresis and multimodality therapy in patients with T-cell cutaneous lymphomas: Real-life experience in Argentina.
    Baquero Rey JA; Zambrano Franco EA; Andrade Miranda A; Marciano S; Mazzuoccolo LD; Enz PA
    J Clin Apher; 2021 Dec; 36(6):815-822. PubMed ID: 34478581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome.
    McGirt LY; Thoburn C; Hess A; Vonderheid EC
    Photodermatol Photoimmunol Photomed; 2010 Aug; 26(4):182-91. PubMed ID: 20626820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015.
    Ling YL; Huang X; Mitri G; Lovelace B; Pham A; Knobler R; Li X; Gao X
    J Dermatolog Treat; 2020 Feb; 31(1):91-98. PubMed ID: 30892982
    [No Abstract]   [Full Text] [Related]  

  • 8. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
    Stevens SR; Baron ED; Masten S; Cooper KD
    Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging and management of cutaneous T-cell lymphoma.
    Scarisbrick JJ
    Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early intervention of extracorporeal photopheresis for advancing/progressing cutaneous T-cell lymphoma.
    Aires D; Abhyankar S
    Hematol Oncol; 2023 Dec; 41(5):809-816. PubMed ID: 37974524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides.
    Lewis DJ; Duvic M
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28338261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma--the Düsseldorf and Munich experience.
    Prinz B; Behrens W; Hölzle E; Plewig G
    Arch Dermatol Res; 1995; 287(7):621-6. PubMed ID: 8534123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
    Quaglino P; Fierro MT; Rossotto GL; Savoia P; Bernengo MG
    Br J Dermatol; 2004 Feb; 150(2):327-36. PubMed ID: 14996105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 75% Complete Response and 15% Partial Response to Extracorporeal Photopheresis Combined With Other Therapies in Resistant Early Stage Cutaneous T-Cell Lymphoma.
    Seremet S; Abhyankar S; Herd TJ; Aires D
    J Drugs Dermatol; 2016 Oct; 15(10):1212-1216. PubMed ID: 27741338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
    Quaglino P; Knobler R; Fierro MT; Savoia P; Marra E; Fava P; Bernengo MG
    Int J Dermatol; 2013 Nov; 52(11):1308-18. PubMed ID: 23786842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of cutaneous T-cell lymphoma with photopheresis.
    Zic JA
    Dermatol Ther; 2003; 16(4):337-46. PubMed ID: 14686977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial differences in the use of extracorporeal photopheresis for mycosis fungoides.
    Agi C; Kuhn D; Chung J; Zampella J; Hinds G
    J Dermatolog Treat; 2015 Jun; 26(3):266-8. PubMed ID: 25034002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution.
    Gottlieb SL; Wolfe JT; Fox FE; DeNardo BJ; Macey WH; Bromley PG; Lessin SR; Rook AH
    J Am Acad Dermatol; 1996 Dec; 35(6):946-57. PubMed ID: 8959954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD209
    Ni X; Austin M; Langridge T; Bojaxhi P; Bijani P; Wang X; Duvic M
    Photodermatol Photoimmunol Photomed; 2020 Jul; 36(4):290-298. PubMed ID: 32187738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
    Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
    Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.